Concord Biotech Share Price Today

Concord Biotech closes trading window from Oct 1 for Q2FY27 results

Trading window closes from October 1, 2026, until 48 hours post-results declaration. Restriction applies to Q2FY27 and H1FY27 unaudited financial results. Designated persons and immediate relatives barred from trading during this period. Compliance mandated under SEBI (Prohibition of Insider Trading) Regulations, 2015.

Concord Biotech sets Sept 25 start for postal ballot on bonus issue

Remote e-voting for Concord Biotech's bonus issue starts September 25, 2026. Shareholder cut-off date for voting eligibility is September 18, 2026. Proposed 1:1 bonus issue requires capitalising ₹10.46 crore from securities premium. Authorised share capital increase to ₹22 crore included in postal ballot resolutions.

Concord Biotech to host analyst meet on Sep 23 in Ahmedabad

Concord Biotech to host group analyst meet on September 23, 2026. Session scheduled for 12:30 pm in Ahmedabad. Event organised as part of JP Morgan Healthcare Trip. Discussions limited to publicly available information.

Concord Biotech to host investor meet on August 26 in Ahmedabad

Concord Biotech will host an investor meet on August 26, 2026. The group meeting is organized by Phillip Capital PCG in Ahmedabad. Sessions will run from 1:00 pm to 3:00 pm IST. Only publicly available information will be discussed. No unpublished price-sensitive information will be shared.

Concord Biotech Q1 FY27 revenue rises 26% to ₹257 crore on API strength

Concord Biotech delivered strong Q1 FY27 results with revenue growing 26% to ₹257 crore and PAT up 31% to ₹58 crore. Driven by a 42% rise in API sales and 46% export growth, the company expanded EBITDA margins to 32%. Management highlighted broad-based growth across product categories and a robust pipeline, positioning the firm to leverage its existing capacity for long-term value creation.

Concord Biotech loan limits approved despite institutional dissent at AGM

Concord Biotech Limited shareholders approved all six resolutions at its 41st AGM, including enhanced loan limits to group companies. While the resolution passed with 81.64% support, it faced significant opposition from institutional investors (56.60% against), highlighting a governance divergence. Other resolutions, including dividend declaration and director appointments, received near-unanimous support.